Details about the Deal Making Activities of Novartis over a Five Year Period.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36972) has announced the addition of PharmaDeals(R) Deal Making Spotlight on Novartis to their offering.

We have published a series of reports dedicated to assisting companies in business development and deal making in the pharmaceutical & healthcare sectors.

Published reports include:

--Deal Making Spotlight on Pfizer 

--Deal Making Spotlight on sanofi-aventis 

--Deal Making Spotlight on GlaxoSmithKline 

--Deal Making Spotlight on Johnson & Johnson

--Deal Making Spotlight on Novartis

This report "Deal Making Spotlight on Novartis" details the deal making activities of Novartis, from 2000 up to and including the whole of 2005. If you are looking to partner with big pharma, this report is crucial to your deal making strategy.

Each report is:

--Insightful - Presents and discusses the deal making activities of the company and its subsidiaries over a 5-year period. Key trends are identified, providing you with full information about your potential partner.

--Analytical - Analysis of deal making trends identifies: which phase each company deals at; how much each company pays for deals; what type of deals are made; what therapy areas are represented. This ensures you have the full information you need to plan the next step towards your deal.

--Comprehensive - The deal making profile covers all deals made by the company and its subsidiaries between 2000 and 2005. Commentary is supported by full lists of deals made as well as articles that provide in-depth analysis of key deals made by the company in question

Topics Covered

--SPOTLIGHT OVERVIEW

--SPOTLIGHT FOCUS

--Novartis

--Deal Making Subsidiaries

--DEAL MAKING

--Deal Making Overview

--Financial Information

--Partnering Companies

--Interest Areas

--Licensing Deal Focus

--R&D Deal Activity

--Marketing Deal Activity

--NOVARTIS DEALS 2000-2005

--FIELD DEFINITIONS

--Deal Types

--Product Types

--Interest Area

--Company Types

--NOVARTIS DEALS 2000-2005

--CATALOGUE

--CATALOGUE INDEX

--Index of Partnering Companies

--Index of Interest Areas

--APPENDICES

--Indications and Interest Areas

--Novartis articles reprinted from the PharmaDeals(R) Review

--GUIDE TO PHARMADEALS AGREEMENTS

--LIST OF FIGURES

--Figure 1 The proportion of the total annual revenues of the top 10 global pharmaceutical companies in 2004 generated by each company.

--Figure 2 The total number of deals made each year between 2000 and 2005 by Novartis compared to the average number of deals made by the top 10 global pharmaceutical companies.

--Figure 3 Deal making activities of Novartis between 2000 and 2005.

--Figure 4 Percentage of deals made by Novartis between 2000 and 2005 involving each deal type.

--Figure 5 Comparison of the total potential deal values based on deal type.

--Figure 6 Comparison of deal structure financial components based on deal type.

--Figure 7 Proportion of partnering companies by size and type.

--Figure 8 Number of deals involving each therapy interest area.

--Figure 9 Number of deals involving each technology interest area.

--Figure 10 In- and out-licensing deals by product area.

--Figure 11 In- and out-licensing deals by phase of product development.

--Figure 12 Number of licensing deals by therapy interest area.

--Figure 13 Number of licensing deals by technology interest area.

--Figure 14 Number of R&D deals by therapy interest area.

--Figure 15 Number of R&D deals by technology interest area.

--Figure 16 Proportion of marketing deals by territory.

--Figure 17 Number of marketing deals by therapy interest area.

For more information visit http://www.researchandmarkets.com/reports/c36972